Synergy Asset Management LLC Purchases 152,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Synergy Asset Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 391.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 191,805 shares of the biopharmaceutical company's stock after acquiring an additional 152,788 shares during the quarter. Gilead Sciences makes up about 1.3% of Synergy Asset Management LLC's portfolio, making the stock its 17th biggest holding. Synergy Asset Management LLC's holdings in Gilead Sciences were worth $17,309,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GILD. nVerses Capital LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at $29,000. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Quarry LP acquired a new position in Gilead Sciences in the 2nd quarter valued at $43,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Piper Sandler lifted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Morgan Stanley upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Robert W. Baird lifted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Finally, Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Trading Up 1.2 %

Shares of NASDAQ:GILD traded up $1.18 during midday trading on Monday, reaching $98.38. The company's stock had a trading volume of 10,509,683 shares, compared to its average volume of 7,014,577. The firm has a 50 day moving average price of $92.42 and a two-hundred day moving average price of $85.96. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $99.45. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $122.61 billion, a price-to-earnings ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the business earned $2.29 EPS. The firm's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares of the company's stock, valued at $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.